Personal information

Other IDs

Scopus Author ID: 55618890700
ResearcherID: S-2806-2016

Countries

Türkiye

Activities

Collapse all

Employment (1)

Necmettin Erbakan University Faculty of Science: Konya, TR

2017-12-18 to present | Asisst Professor (Biotechnology)
Employment
Source: Self-asserted source
Egemen FOTO

Education and qualifications (2)

Necmettin Erbakan University: Konya, TR

2017-12-18 to present | Asst Professor (Biotechnology, Faculty of Science)
Education
Source: Self-asserted source
Egemen FOTO

Hacettepe Univesity Faculty of Science: Ankara, Beytepe, TR

2009 to 2016 | PhD (Molecular Biology)
Education
Source: Self-asserted source
Egemen FOTO

Works (10)

Design, Synthesis, and Biological Evaluation of Some Novel Retinoid Derivatives

Letters in Drug Design & Discovery
2024-11 | Journal article
DOI: 10.2174/0115701808243556231017055256
Contributors: Dilan Konyar; Egemen Foto; Fatma Zilifdar Foto; Mehmet Erdem Buyukbingol
Source: check_circle
Crossref

Antioxidative and antiproliferative effects of propolis-reduced silver nanoparticles

Advances in nano research
2021 | Journal article
DOI: 10.12989/ANR.2021.10.2.139
Source: Self-asserted source
Egemen FOTO

Discovery of 5-(or 6)-benzoxazoles and oxazolo[4,5-b]pyridines as novel candidate antitumor agents targeting hTopo IIα

Bioorganic Chemistry
2021-07 | Journal article
DOI: 10.1016/j.bioorg.2021.104913
Part of ISSN: 0045-2068
Source: Self-asserted source
Egemen FOTO

Benzoxazines as new human topoisomerase I inhibitors and potential poisons

DARU Journal of Pharmaceutical Sciences
2020-06-12 | Journal article
DOI: 10.1007/s40199-019-00315-x
Contributors: Egemen Foto; Çigdem Özen; Fatma Zilifdar; Betül Tekiner-Gülbaş; İlkay Yıldız; Esin Akı-Yalçın; Nuran Diril; İsmail Yalçın
Source: check_circle
Crossref

Biological evaluation and pharmacophore modeling of some benzoxazoles and their possible metabolites.

Archiv der Pharmazie
2018-01 | Journal article
DOI: 10.1002/ardp.201700265
PMID: 29359805
Contributors: Zilifdar F; Foto E; Ertan-Bolelli T; Aki-Yalcin E; Yalcin I; Diril N
Source: Self-asserted source
Egemen FOTO via Europe PubMed Central

Inhibition of DNA topoisomerases by a series of benzoxazoles and their possible metabolites

Letters in Drug Design & Discovery
2018-01 | Journal article
DOI: 10.2174/1570180815666180124143246
Part of ISSN: 1570-1808
Contributors: Fatma Zilifdar; Egemen Foto; Tugba Ertan-Bolelli; Ilkay Yildiz; Esin Aki-Yalcin; Nuran Diril
Source: Self-asserted source
Egemen FOTO via Crossref Metadata Search

Vibrational spectroscopic analysis, molecular dynamics simulations and molecular docking study of 5-nitro-2-phenoxymethyl benzimidazole

Journal of Molecular Structure
2017-02 | Journal article
DOI: 10.1016/j.molstruc.2016.09.059
Contributors: Vidya V. Menon; Egemen Foto; Y. Sheena Mary; Esin Karatas; C. Yohannan Panicker; Gözde Yalcin; Stevan Armaković; Sanja J. Armaković; C. Van Alsenoy; Ilkay Yildiz
Source: check_circle
Crossref

Antiproliferative and Genotoxic Activities in L929 and HeLa Cell Lines, Mutagenic Effects in Salmonella Strains of Novel Benzoxazole Derivatives

Latin American Journal of Pharmacy
2016-08-20 | Journal article
Part of ISSN: ISSN 0326 2383
Source: Self-asserted source
Egemen FOTO

Genotoxic potentials and eukaryotic DNA topoisomerase i inhibitory effects of some benzoxazine derivatives

Medicinal Chemistry Research
2014 | Journal article
DOI: 10.1007/s00044-013-0658-5
EID:

2-s2.0-84893724369
Contributors: Zilifdar, F.; Alper-Hayta, S.; Yilmaz, S.; Kaplan-Özen, C.; Foto, E.; Aydoǧan, Z.; Yildiz, I.; Aki, E.; Yalçin, I.; Diril, N.
Source: Self-asserted source
Egemen FOTO via Scopus - Elsevier

Benzothiazole derivatives as human DNA topoisomerase IIα inhibitors

Medicinal Chemistry Research
2013 | Journal article
DOI: 10.1007/s00044-013-0577-5
EID:

2-s2.0-84886085541
Contributors: Kaplan-Ozen, C.; Tekiner-Gulbas, B.; Foto, E.; Yildiz, I.; Diril, N.; Aki, E.; Yalcin, I.
Source: Self-asserted source
Egemen FOTO via Scopus - Elsevier

Peer review (4 reviews for 1 publication/grant)

Review activity for Medicinal chemistry research. (4)
How many people are using ORCID?